Oxford AstraZeneca vaccine granted Emergency Use Listing : WHO


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Oxford AstraZeneca vaccine granted Emergency Use Listing : WHO
As the vaccine earns approval from WHO now it is eligible for distribution in low and middle-income countries

Paving the way for Covid-19 vaccines to be distributed to low-income countries, the World Health Organisation on Monday granted emergency use listing (EUL) for the Oxford-Astrazeneca coronavirus vaccine manufactured by India's Serum Institute and South Korea's AstraZeneca-SKBio.

The authorisation will allow SII, the world’s biggest vaccine maker, to begin supplies of the Oxford vaccine to the WHO-backed COVAX initiative. Some 190 countries have joined the programme, which was established to ensure equitable distribution of vaccines.

Earlier, Serum Institute CEO Adar Poonawalla had said it would sell each dose at $3 for low-income countries. Besides the Oxford vaccine, WHO listed Pfizer and BioNTech's Covid-19 shot for emergency use on December 31.

The approval came after WHO's Strategic Advisory Group of Experts on Immunization (SAGE) reviewed the vaccine on February 8. The SAGE has recommended the vaccine for all age groups 18 and above.

"Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk, contributing to the COVAX Facility’s goal of equitable vaccine distribution," Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products, said in a statement.

What does emergency use listing by WHO mean?
An EUL by WHO is an endorsement of sorts that will enable speedy pick-up of the vaccine by countries that lack an elaborate regulatory setup. According to WHO, its Emergency Use Listing assesses the quality, safety and efficacy of Covid-19 vaccines and is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines.

In the case of the AstraZeneca/Oxford vaccine, WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements, the statement said. The process took four weeks.

Story Credit

https://www.indiatoday.in/coronavirus-outbreak/story/serum-institute-who-emergency-use-listing-oxford-covid-vaccine-1769586-2021-02-15 

Tags : #OxfordUniversity #AstraZeneca #WHO #VaccineApproval #LowandMiddleincomeCountries #SerumInstitute #AdarPoonawala

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026